Structure Therapeutics (GPCR) Stock Rises 10% as GLP-1 Pill Tops Lilly and Novo

Posted on by

TLDR

  • Structure Therapeutics’ oral GLP-1 medication aleniglipron delivered a 16.3% placebo-adjusted weight reduction over 44 weeks in its Phase 2 ACCESS II trial
  • The findings outperformed Phase 2 data from rival oral GLP-1 treatments: Novo Nordisk’s (13.6%) and Eli Lilly’s (12.4%)
  • Weight loss exhibited no plateauing signs— a key distinction from competitors
  • GPCR shares climbed approximately 10% on Monday to roughly $59.80 following the announcement
  • A Phase 2 end-of-study meeting with the FDA is scheduled for Q2 2026, while Phase 3 trials are set to launch in the second half of 2026

Structure Therapeutics announced robust Phase 2 results for its oral GLP-1 drug aleniglipron on Monday, driving GPCR shares up by about 10% in morning trading.

Structure Therapeutics Inc. (GPCR)
GPCR Stock Card

The ACCESS II trial demonstrated 16.3% placebo-adjusted weight loss for the 180 mg dose and 16.0% for the 240 mg dose after 44 weeks. Neither dosage exhibited any plateauing signs.

These results compare favorably to competitors. Novo Nordisk’s oral Wegovy achieved 13.6% weight loss in Phase 3. Eli Lilly’s orforglipron delivered approximately 12.4% in Phase 2 and 11.2% in Phase 3.

Preliminary data from December indicated a 14.2% weight loss for a lower dose. Patients who continued on that lower dose for 53 weeks ultimately achieved 16% weight loss, indicating sustained benefits over time.

Tolerability data remained strong. In the ACCESS Open Label Extension trial, the discontinuation rate due to adverse events was only 2%. The body composition study reported a 3.4% rate. Structure employs a low 2.5 mg starting dose, which seems to help patients remain on the medication.

The findings are now sparking merger and acquisition (M&A) discussions. H.C. Wainwright analyst Ananda Ghosh had previously identified aleniglipron earlier this month as “the most acquirable asset in obesity.” The firm increased its price target to $114. Citizens maintained its Market Outperform rating but reduced its target to $113.

Analyst Reactions

Leerink Partners reaffirmed its Outperform rating and $90 price target following the release of the data. The firm emphasized the strong tolerability profile and dose-response relationship as key strengths.

RBC Capital Markets took a more cautious stance. Analyst Trung Huynh pointed out that orforglipron had similar performance in Phase 2 but showed weaker results in Phase 3. He highlighted the unusually low weight gain rate in the placebo group as a statistical anomaly to monitor. RBC retained its Outperform rating on Lilly with a $1,250 price target.

“It’s hard to describe these results as significantly distinct from Orfo or oral Wegovy until we have a more comprehensive data set,” Huynh stated.

What Comes Next

Structure intends to hold an end-of-Phase 2 meeting with the FDA in Q2 2026. Phase 3 trials are expected to launch in the second half of 2026. The Phase 2 data from both high doses will determine which dosage proceeds to the next stage.

The stock remains down 23% year-to-date going into Monday’s trading session, though it has risen 155% over the past 12 months. At $59.80, the stock trades significantly below analyst consensus targets, which span from $90 to $140.

Cantor Fitzgerald had earlier identified this 44-week data release as a potential catalyst for the stock. That prediction turned out to be accurate.

Monday’s price movement lifted GPCR’s market capitalization to roughly $3.81 billion.